459 related articles for article (PubMed ID: 23988576)
1. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
3. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
4. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
5. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
[TBL] [Abstract][Full Text] [Related]
6. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
[TBL] [Abstract][Full Text] [Related]
7. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R
Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156
[TBL] [Abstract][Full Text] [Related]
8. Analysis of diagnosis and treatment for pancreatic neuroendocrine neoplasms: results of 47 cases in a single institution.
Lin XS; Zhu CL; Liu CH; Xie F; Zhou HC; Huang Q
Hepatogastroenterology; 2014; 61(136):2383-6. PubMed ID: 25699387
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.
Larghi A; Capurso G; Carnuccio A; Ricci R; Alfieri S; Galasso D; Lugli F; Bianchi A; Panzuto F; De Marinis L; Falconi M; Delle Fave G; Doglietto GB; Costamagna G; Rindi G
Gastrointest Endosc; 2012 Sep; 76(3):570-7. PubMed ID: 22898415
[TBL] [Abstract][Full Text] [Related]
10. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
[TBL] [Abstract][Full Text] [Related]
11. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Nasir A; Coppola D; Wick M; Kvols L
Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.
Durante C; Boukheris H; Dromain C; Duvillard P; Leboulleux S; Elias D; de Baere T; Malka D; Lumbroso J; Guigay J; Schlumberger M; Ducreux M; Baudin E
Endocr Relat Cancer; 2009 Jun; 16(2):585-97. PubMed ID: 19240182
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
[TBL] [Abstract][Full Text] [Related]
15. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
Pape UF; Berndt U; Müller-Nordhorn J; Böhmig M; Roll S; Koch M; Willich SN; Wiedenmann B
Endocr Relat Cancer; 2008 Dec; 15(4):1083-97. PubMed ID: 18603570
[TBL] [Abstract][Full Text] [Related]
18. Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems.
Pomianowska E; Gladhaug IP; Grzyb K; Røsok BI; Edwin B; Bergestuen DS; Mathisen O
Scand J Gastroenterol; 2010 Aug; 45(7-8):971-9. PubMed ID: 20441530
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors.
Gao SW; Huang CS; Huang XT; Chen LH; Chen W; Cai JP; Yin XY
Pancreas; 2019 Jul; 48(6):795-798. PubMed ID: 31210659
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
Özaslan E; Demir S; Karaca H; Güven K
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
